stockportfolio.pro
Iovance Biotherapeutics, Inc. (IOVA)
Healthcare · Biotechnology · NasdaqGM
Iovance Biotherapeutics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.19M | $164.07M | $263.50M |
| Gross profit | — | — | — | — | — | — | — | $156,000 | $70.82M | $90.32M |
| Net income | $-52.89M | $-92.06M | $-123.58M | $-197.56M | $-259.58M | $-342.25M | $-395.89M | $-444.04M | $-372.18M | $-390.98M |
| Net margin | — | — | — | — | — | — | — | -37345.4% | -226.8% | -148.4% |
Source: Iovance Biotherapeutics, Inc. SEC filings (10-K). 18 years of history available in the interactive view.
Explore 18 years of Iovance Biotherapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track IOVA in your portfolio →
Iovance Biotherapeutics, Inc. financial history by metric
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Iovance Biotherapeutics, Inc. — frequently asked questions
What is Iovance Biotherapeutics, Inc.'s revenue?
Iovance Biotherapeutics, Inc. (IOVA) reported revenue of $263.50M for fiscal year 2025, up 60.6% from the prior year, according to its SEC filings.
Is Iovance Biotherapeutics, Inc. profitable?
No — IOVA reported a net loss of $-390.98M in fiscal 2025.
What is IOVA's P/E ratio?
Iovance Biotherapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Iovance Biotherapeutics, Inc. have?
As of fiscal year 2025, IOVA carried roughly $1.00M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Iovance Biotherapeutics, Inc.'s gross margin?
IOVA's gross margin was 34.3% in fiscal 2025 — gross profit of $90.32M on revenue of $263.50M.
What is Iovance Biotherapeutics, Inc.'s market cap?
Iovance Biotherapeutics, Inc. (IOVA) has a market capitalization of about $1.73B, based on the latest data in our nightly-refreshed cache.
When does Iovance Biotherapeutics, Inc.'s fiscal year end?
IOVA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Iovance Biotherapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 18 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.